Bayer

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer spread or death in men with high-risk biochemical recurrence of prostate cancer. About 985 men will receive either darolutamide plus ADT or a placebo plus ADT for up to 24 months. The …

This early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing nearby he…

This study monitors the safety and side effects of the drug sorafenib (Nexavar) in people with a type of advanced thyroid cancer that cannot be removed by surgery. Over 450 participants are being followed for up to 2 years to track side effects, how long they stay on treatment, a…

This study tests a new drug called aficamten in 36 Japanese adults with a heart condition that makes the heart muscle too thick, making it hard to pump blood. The drug works by relaxing the heart muscle to improve blood flow. Researchers will check if it reduces symptoms and impr…

This study tests a new drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific changes (mutations) in the EGFR or HER2 genes. The drug aims to block these abnormal proteins to stop cancer growth. The trial involves about 370 participants and will …

This study tests a gene therapy called BAY2599023 in 11 adults with severe hemophilia A. The treatment delivers a healthy copy of the factor VIII gene so the body can produce its own clotting protein. The goal is to find the safest and most effective dose to reduce or stop bleedi…

This study tracks the safety and effectiveness of darolutamide in men with prostate cancer that has not spread but is no longer responding to standard hormone therapy. Over 800 participants are being observed in real-world clinics to see how well the drug works and what side effe…

This study follows over 1,000 Japanese adults with renal anemia—a condition where the kidneys don't produce enough hormone to make red blood cells—who are taking the drug Molidustat. Researchers are monitoring safety and whether the drug boosts red blood cell counts over up to 2 …

This early-stage study tests a new drug, BAY 2965501, that aims to activate the body's immune T-cells to fight advanced solid tumors (like certain skin, kidney, stomach, and lung cancers). The study involves about 284 participants and will test the drug alone or combined with oth…

This study offers ongoing darolutamide treatment to cancer patients who previously took part in Bayer-sponsored studies and are still benefiting from the drug. About 402 participants will continue their same dose and attend regular check-ups. The main goal is to monitor any side …

This study looks at how well the drug darolutamide (combined with hormone therapy, and sometimes chemotherapy) works for men whose prostate cancer has spread and still responds to hormones. About 1,600 men from Europe will be followed during their normal treatment. The goal is to…

This study is for people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study and are benefiting from it. They can keep taking the same dose to see how safe it is and how well they tolerate it over time. The study involves about 13 participa…

This study tested the safety of a drug called riociguat in 24 children aged 6 to 17 with pulmonary arterial hypertension (PAH), a rare condition where high blood pressure affects the lungs. The drug was given in doses adjusted for each child's age, sex, and weight. The goal was t…

This early-phase trial tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. It is given alone or with another immunotherapy (pembrolizumab) to about 129 adults whose cancers have not responded to standard …

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to a similar group that got ADT…

This study looks at children with congenital heart disease who take the blood thinner rivaroxaban after a Fontan procedure. The goal is to see how often serious or minor bleeding happens in real-world use. Researchers will collect data from medical records of 61 children for up t…

This study tests a new drug, elinzanetant, to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to …

This study looks at medical records from over 600 Indian adults with chronic heart failure who were prescribed the drug vericiguat between 2022 and 2023. Researchers want to see how well the drug works and how safe it is in everyday medical practice. No new treatments or tests ar…

This study reviews medical records of 1,200 Indian adults with chronic kidney disease and type 2 diabetes who started taking finerenone between August 2022 and April 2024. Researchers will look at how doctors prescribed the drug, dose changes, and lab results like kidney function…

This study looks at how the drug Jivi (damoctocog alfa pegol) works for people with Hemophilia A in real-world settings, not just in controlled trials. Researchers are tracking bleeding episodes, side effects, and how satisfied patients and doctors are with the treatment. About 3…

This study looks at medical records from 10,000 people who had sepsis (blood poisoning) and blood clots in their veins (VTE) while in the ICU. Researchers want to see if a serious clotting disorder called DIC happened before the blood clots formed. No new treatments or tests are …

This study checks how many women with multiple sclerosis (MS) used the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to see if there are enough cases to study whether the drug affects pregnancy outcomes like birth…

This study watches people with hemophilia A who are already using Jivi (a long-acting clotting factor) to prevent bleeding. Researchers will collect safety information during regular doctor visits for at least 4 years. No new treatment is given—just observation of real-world use.…

This study collects data from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer to see how doctors actually intensify treatment over time. No new treatments or advice are given—researchers simply observe what happens in routine care. The goal i…

This study observes 100 Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will track heart-related side effects and other medical problems during treatment. No extra vi…

This study watches how doctors prescribe finerenone to people with chronic kidney disease and type 2 diabetes in everyday care. It does not test a new treatment—just collects information from medical records and doctor visits over 12 months. About 4,600 adults will take part to h…

This study looks at how well the eye injection aflibercept 8 mg works for people with vision loss from age-related macular degeneration (nAMD) or diabetic macular edema (DME). Researchers will collect data from 2500 adults already prescribed the drug by their doctors, tracking vi…